These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 11177319)

  • 21. Improving protection for research subjects.
    Steinbrook R
    N Engl J Med; 2002 May; 346(18):1425-30. PubMed ID: 11986426
    [No Abstract]   [Full Text] [Related]  

  • 22. New guidance on reviews by central institutional review boards (IRBs).
    Maloney DM
    Hum Res Rep; 2005 May; 20(5):1-2. PubMed ID: 16175714
    [No Abstract]   [Full Text] [Related]  

  • 23. Variation in local institutional review board evaluations of a multicenter patient safety study.
    Thompson DA; Kass N; Holzmueller C; Marsteller JA; Martinez EA; Gurses AP; Kanchuger M; Schwann N; Gibson CS; Bauer L; Pronovost PJ
    J Healthc Qual; 2012; 34(4):33-9. PubMed ID: 22060010
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Institutional review boards and medical devices.
    Less JR; Alpert S; Nightingale SL
    JAMA; 1994 Sep; 272(12):968-9. PubMed ID: 8084066
    [No Abstract]   [Full Text] [Related]  

  • 25. Quantifying the federal minimal risk standard: implications for pediatric research without a prospect of direct benefit.
    Wendler D; Belsky L; Thompson KM; Emanuel EJ
    JAMA; 2005 Aug; 294(7):826-32. PubMed ID: 16106008
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Economies of scale in institutional review boards.
    Wagner TH; Cruz AM; Chadwick GL
    Med Care; 2004 Aug; 42(8):817-23. PubMed ID: 15258484
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Review of multicenter studies by multiple institutional review boards: characteristics and outcomes for perinatal studies implemented by a multicenter network.
    Abramovici A; Salazar A; Edvalson T; Gallagher N; Dorman K; Tita A;
    Am J Obstet Gynecol; 2015 Jan; 212(1):110.e1-6. PubMed ID: 25088862
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Toward a more comprehensive approach to protecting human subjects: the interface of data safety monitoring boards and institutional review boards in randomized clinical trials.
    Gordon VM; Sugarman J; Kass N
    IRB; 1998; 20(1):1-5. PubMed ID: 11655324
    [No Abstract]   [Full Text] [Related]  

  • 29. A systematic review of the empirical literature evaluating IRBs: what we know and what we still need to learn.
    Abbott L; Grady C
    J Empir Res Hum Res Ethics; 2011 Mar; 6(1):3-19. PubMed ID: 21460582
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Waivers proposed for emergency studies.
    Wolfgang L
    Science; 1995 Oct; 270(5233):25-6. PubMed ID: 7569946
    [No Abstract]   [Full Text] [Related]  

  • 31. Institutional review board variability in minimal-risk multicenter urogynecology studies.
    Harvie HS; Lowenstein L; Omotosho TB; Sanses T; Molden S; Hardy J; Brubaker L;
    Female Pelvic Med Reconstr Surg; 2012; 18(2):89-92. PubMed ID: 22453318
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multicenter trials and subject eligibility: should local IRBs play a role?
    Freedman B
    IRB; 1994; 16(1-2):1-6. PubMed ID: 11652320
    [No Abstract]   [Full Text] [Related]  

  • 33. Burdens on research imposed by institutional review boards: the state of the evidence and its implications for regulatory reform.
    Silberman G; Kahn KL
    Milbank Q; 2011 Dec; 89(4):599-627. PubMed ID: 22188349
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety boards must report their conclusions to IRBs.
    Maloney DM
    Hum Res Rep; 1999 Oct; 14(10):3. PubMed ID: 11658061
    [No Abstract]   [Full Text] [Related]  

  • 35. The institutional review board and beyond: future challenges to the ethics of human experimentation.
    Edgar H; Rothman DJ
    Milbank Q; 1995; 73(4):489-506. PubMed ID: 7491097
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Application for academic multicenter studies at German ethical review boards].
    Gökbuget N; Naumann R;
    Onkologie; 2013; 36 Suppl 2():29-35. PubMed ID: 23549034
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Streamlining IRB review in multisite trials through single-study IRB Cooperative Agreements: experience of the Beta-Carotene and Retinol Efficacy Trial (CARET).
    Thornquist MD; Edelstein C; Goodman GE; Omenn GS
    Control Clin Trials; 2002 Feb; 23(1):80-6. PubMed ID: 11852169
    [TBL] [Abstract][Full Text] [Related]  

  • 38. How institutional review boards (IRBs) can handle adverse event reports.
    Maloney DM
    Hum Res Rep; 2006 Jan; 21(1):1-3. PubMed ID: 16789305
    [No Abstract]   [Full Text] [Related]  

  • 39. Institutional review boards (IRBs) would have an increased role in international research.
    Maloney DM
    Hum Res Rep; 2002 Oct; 17(10):9. PubMed ID: 12731498
    [No Abstract]   [Full Text] [Related]  

  • 40. Grinding to a halt: the effects of the increasing regulatory burden on research and quality improvement efforts.
    Infectious Diseases Society of America
    Clin Infect Dis; 2009 Aug; 49(3):328-35. PubMed ID: 19566438
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.